Currax Pharmaceuticals

Currax is a specialty pharmaceutical company focused on developing and commercializing therapies that address chronic conditions with significant unmet need. The company’s strategy is grounded in patient-centered insights, using real-world experience to inform solutions that improve access, adherence, and treatment outcomes.

One of Currax’s key therapies is CONTRAVE®, the only FDA-approved oral weight-loss medication that combines extended-release naltrexone and bupropion. CONTRAVE works in two ways to help reduce hunger and control cravings. CONTRAVE is a non-stimulant prescription weight-management medication for appropriate patients.